WVE News and Press, Wave Life Sciences Ltd. From 08/11/22

Wave Life Sciences press release ( NASDAQ: WVE ): Q2 GAAP EPS of -$0.62 misses by $0.08 . Revenue of $0.37M (-86.7% Y/Y). As of June 30, 2022, Wave had $148.2 million in cash, cash equivalents and short-term investments For further details see:...

WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for editing Data for ongo...

Wave Life Sciences ( NASDAQ: WVE ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.53 (+32.1% Y/Y) and the consensus Revenue Estimate is $3M (+7.9% Y/Y). Over the last 3 months, EPS estimates ...

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and confe...

Two new Breakout Stocks for Week 30 with better than 10% short-term upside potential and one Dow 30 pick. Average cumulative returns now up to +96.9% YTD. High frequency breakouts continue with peak gains in 1 of 4 picks above 10% led by TA gaining +13.1% and next top gains were in SP...

Two new Breakout Stocks for Week 29 with better than 10% short-term upside potential and one Dow 30 Picks. Average cumulative returns now up to +88.6% YTD. No picks broke 10% in less than a week with top gains in HOWL +9.4% and VRDN 6.5% and the Negative MDA trading signal continues f...

Two new Breakout Stocks for Week 28 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +86.9% YTD. No picks broke 10% in less than a week and the Negative Momentum Gauge® warning signals continue negative through 27 out of the...

Gainers: 22nd Century Group (XXII) +29%. Wave Life Sciences WVE +16%. Codex DNA (DNAY) +13%. F-star Therapeutics (FSTX) +12%. Sorrento Therapeutics (SRNE) +12%. Losers: Athira Pharma ATHA -70%. Neptune Wellness Solutions NEPT -32%. 4D pharma (LBPS)...

Wave Life Sciences (NASDAQ:WVE) has disclosed a share purchase by 10% owner Ra Capital Management. Ra Capital Management bought over 9.48M shares of the company's ordinary shares at $2.15 in a transaction dated June 16, 2022. It now becomes the beneficial owner of 17,202,009 shares of the iss...

Wave Life Sciences (NASDAQ:WVE) priced an underwritten offering of 25.5M shares at an offering price of $2.15/share and to RA Capital Management, in lieu of ordinary shares, pre-funded warrants to purchase up to 7.09M shares. The per share offering price for the ordinary shares represent...